Loading...

Novo Nordisk A/S

NVONYSE
Healthcare
Drug Manufacturers - General
$69.02
$0.51(0.74%)

Novo Nordisk A/S (NVO) Stock Overview

Explore Novo Nordisk A/S’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

A

Score: 84.0/100

Key Financials

Market Cap305.6B
P/E Ratio18.54
EPS (TTM)$3.63
ROE0.81%

AI Price Forecasts

1 Week$74.81
1 Month$73.11
3 Months$61.42
1 Year Target$118.71

NVO Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Novo Nordisk A/S (NVO) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of A, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $118.71.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 18.54 and a market capitalization of 305.6B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Revenue Growth
25.03%
25.03%
Profit Growth
$23.56
20.68%
EPS Growth
$23.56
21.42%
Operating Margin
44.53%
25.12%
ROE
81.24%
20.68%
Dividend Yield
0.00%
39.85%

Analyst Recommendations

Strong Buy
0
Buy
4
Hold
1
Sell
3
Strong Sell
0

Price Targets

Low$156.00
Average$158.67
High$160.00

Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

CEO

Lars Fruergaard Jorgensen

Employees

77,406

Headquarters

Novo Alle 1, Bagsvaerd

Founded

1981

Frequently Asked Questions

;